Novexel SA (Novexel) is a developing stage pharmaceutical company engaged in the discovery and development of antibacterial and antifungal agents for the treatment of bacterial and fungal infections. The product pipeline of Novexel includes; NXL103, NXL104/Ceftazidim, NXL201, NXL105 and NXL104/Ceftaroline. NXL103 is in clinical development stage for the treatment of skin and structure infections and respiratory tract infections. NXL104/Ceftazidim is in clinical development stage to treat hospital and community acquired infections, NXL201 is in pre-clinical stage for the treatment of invasive fungal infections, NXL105 is in pre-clinical stage for the treatment of pseudomonas infections and NXL104/Ceftaroline is also in pre-clinical stage for the treatment of gram-negative and gram-positive infections. In March 2010, AstraZeneca PLC has acquired Novexel. The company is headquartered at Romainville, France.